47.83
-0.33 (-0.69%)
| Previous Close | 48.16 |
| Open | 47.85 |
| Volume | 347,043 |
| Avg. Volume (3M) | 780,450 |
| Market Cap | 1,228,861,184 |
| Price / Book | 4.76 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -3.23 |
| Total Debt/Equity (MRQ) | 0.07% |
| Current Ratio (MRQ) | 33.87 |
| Operating Cash Flow (TTM) | -84.02 M |
| Levered Free Cash Flow (TTM) | -53.00 M |
| Return on Assets (TTM) | -19.03% |
| Return on Equity (TTM) | -26.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Tourmaline Bio, Inc. | Mixed | Mixed |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | -2.0 |
| AI Technical info | NA |
| Technical Oscillators info | 0.0 |
| Technical Moving Averages info | -5.0 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.5% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | -1.7 |
| Final Score | -0.85 |
Select this tab to load the latest available analysis.
|
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 21.93% |
| % Held by Institutions | 90.21% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |